Status of PCSK9 Monoclonal Antibodies in Australia
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication f...
Gespeichert in:
| Veröffentlicht in: | Heart, lung & circulation lung & circulation, 2019-10, Vol.28 (10), p.1571-1579 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1579 |
|---|---|
| container_issue | 10 |
| container_start_page | 1571 |
| container_title | Heart, lung & circulation |
| container_volume | 28 |
| creator | Scherer, Daniel J Nelson, Adam J O’Brien, Richard Kostner, Karam M. Hare, David L. Colquhoun, David M. Barter, Philip J. Aylward, Philip Nicholls, Stephen J. Watts, Gerald F. |
| description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage.
This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy. |
| doi_str_mv | 10.1016/j.hlc.2019.04.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232086121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1443950619303543</els_id><sourcerecordid>2232086121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-44f56a635ab3ded796883827d77db98e6fcbc0ae4358137ca2afea4878d7f9f23</originalsourceid><addsrcrecordid>eNp9kDtPwzAUhS0EouXxA1hQRpYEvxI7YqoqXgIEUmG2HPtauErjYidI_HtSWhiZ7hm-c6T7IXRGcEEwqS6XxXtrCopJXWBeYML30JRwznMqa7r_k1lel7iaoKOUlhgTwVl9iCaMEMylFFNEF73uh5QFl73MFw919hS6YNrQ6Tabdb1vgvWQMt9lsyH1Ubden6ADp9sEp7t7jN5url_nd_nj8-39fPaYG1ayPufclZWuWKkbZsGKupKSSSqsELapJVTONAZr4KyUhAmjqXaguRTSClc7yo7RxXZ3HcPHAKlXK58MtK3uIAxJUcoolhWhZETJFjUxpBTBqXX0Kx2_FMFqo0ot1ahKbVQpzNWoauyc7-aHZgX2r_HrZgSutgCMT356iCoZD50B6yOYXtng_5n_BpRUd80</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232086121</pqid></control><display><type>article</type><title>Status of PCSK9 Monoclonal Antibodies in Australia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Scherer, Daniel J ; Nelson, Adam J ; O’Brien, Richard ; Kostner, Karam M. ; Hare, David L. ; Colquhoun, David M. ; Barter, Philip J. ; Aylward, Philip ; Nicholls, Stephen J. ; Watts, Gerald F.</creator><creatorcontrib>Scherer, Daniel J ; Nelson, Adam J ; O’Brien, Richard ; Kostner, Karam M. ; Hare, David L. ; Colquhoun, David M. ; Barter, Philip J. ; Aylward, Philip ; Nicholls, Stephen J. ; Watts, Gerald F.</creatorcontrib><description>Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage.
This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.</description><identifier>ISSN: 1443-9506</identifier><identifier>EISSN: 1444-2892</identifier><identifier>DOI: 10.1016/j.hlc.2019.04.014</identifier><identifier>PMID: 31104887</identifier><language>eng</language><publisher>Australia: Elsevier B.V</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal, Humanized - pharmacology ; Anticholesteremic Agents - pharmacology ; Atherosclerosis ; Australia - epidemiology ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - epidemiology ; Cardiovascular risk ; Humans ; Incidence ; Lipids ; PCSK9 inhibitors ; Proprotein Convertase 9 - antagonists & inhibitors ; Proprotein Convertase 9 - immunology ; Treatment Outcome</subject><ispartof>Heart, lung & circulation, 2019-10, Vol.28 (10), p.1571-1579</ispartof><rights>2019 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)</rights><rights>Copyright © 2019 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-44f56a635ab3ded796883827d77db98e6fcbc0ae4358137ca2afea4878d7f9f23</citedby><cites>FETCH-LOGICAL-c353t-44f56a635ab3ded796883827d77db98e6fcbc0ae4358137ca2afea4878d7f9f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.hlc.2019.04.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31104887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scherer, Daniel J</creatorcontrib><creatorcontrib>Nelson, Adam J</creatorcontrib><creatorcontrib>O’Brien, Richard</creatorcontrib><creatorcontrib>Kostner, Karam M.</creatorcontrib><creatorcontrib>Hare, David L.</creatorcontrib><creatorcontrib>Colquhoun, David M.</creatorcontrib><creatorcontrib>Barter, Philip J.</creatorcontrib><creatorcontrib>Aylward, Philip</creatorcontrib><creatorcontrib>Nicholls, Stephen J.</creatorcontrib><creatorcontrib>Watts, Gerald F.</creatorcontrib><title>Status of PCSK9 Monoclonal Antibodies in Australia</title><title>Heart, lung & circulation</title><addtitle>Heart Lung Circ</addtitle><description>Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage.
This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Anticholesteremic Agents - pharmacology</subject><subject>Atherosclerosis</subject><subject>Australia - epidemiology</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular risk</subject><subject>Humans</subject><subject>Incidence</subject><subject>Lipids</subject><subject>PCSK9 inhibitors</subject><subject>Proprotein Convertase 9 - antagonists & inhibitors</subject><subject>Proprotein Convertase 9 - immunology</subject><subject>Treatment Outcome</subject><issn>1443-9506</issn><issn>1444-2892</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAUhS0EouXxA1hQRpYEvxI7YqoqXgIEUmG2HPtauErjYidI_HtSWhiZ7hm-c6T7IXRGcEEwqS6XxXtrCopJXWBeYML30JRwznMqa7r_k1lel7iaoKOUlhgTwVl9iCaMEMylFFNEF73uh5QFl73MFw919hS6YNrQ6Tabdb1vgvWQMt9lsyH1Ubden6ADp9sEp7t7jN5url_nd_nj8-39fPaYG1ayPufclZWuWKkbZsGKupKSSSqsELapJVTONAZr4KyUhAmjqXaguRTSClc7yo7RxXZ3HcPHAKlXK58MtK3uIAxJUcoolhWhZETJFjUxpBTBqXX0Kx2_FMFqo0ot1ahKbVQpzNWoauyc7-aHZgX2r_HrZgSutgCMT356iCoZD50B6yOYXtng_5n_BpRUd80</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Scherer, Daniel J</creator><creator>Nelson, Adam J</creator><creator>O’Brien, Richard</creator><creator>Kostner, Karam M.</creator><creator>Hare, David L.</creator><creator>Colquhoun, David M.</creator><creator>Barter, Philip J.</creator><creator>Aylward, Philip</creator><creator>Nicholls, Stephen J.</creator><creator>Watts, Gerald F.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201910</creationdate><title>Status of PCSK9 Monoclonal Antibodies in Australia</title><author>Scherer, Daniel J ; Nelson, Adam J ; O’Brien, Richard ; Kostner, Karam M. ; Hare, David L. ; Colquhoun, David M. ; Barter, Philip J. ; Aylward, Philip ; Nicholls, Stephen J. ; Watts, Gerald F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-44f56a635ab3ded796883827d77db98e6fcbc0ae4358137ca2afea4878d7f9f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Anticholesteremic Agents - pharmacology</topic><topic>Atherosclerosis</topic><topic>Australia - epidemiology</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular risk</topic><topic>Humans</topic><topic>Incidence</topic><topic>Lipids</topic><topic>PCSK9 inhibitors</topic><topic>Proprotein Convertase 9 - antagonists & inhibitors</topic><topic>Proprotein Convertase 9 - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scherer, Daniel J</creatorcontrib><creatorcontrib>Nelson, Adam J</creatorcontrib><creatorcontrib>O’Brien, Richard</creatorcontrib><creatorcontrib>Kostner, Karam M.</creatorcontrib><creatorcontrib>Hare, David L.</creatorcontrib><creatorcontrib>Colquhoun, David M.</creatorcontrib><creatorcontrib>Barter, Philip J.</creatorcontrib><creatorcontrib>Aylward, Philip</creatorcontrib><creatorcontrib>Nicholls, Stephen J.</creatorcontrib><creatorcontrib>Watts, Gerald F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Heart, lung & circulation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scherer, Daniel J</au><au>Nelson, Adam J</au><au>O’Brien, Richard</au><au>Kostner, Karam M.</au><au>Hare, David L.</au><au>Colquhoun, David M.</au><au>Barter, Philip J.</au><au>Aylward, Philip</au><au>Nicholls, Stephen J.</au><au>Watts, Gerald F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Status of PCSK9 Monoclonal Antibodies in Australia</atitle><jtitle>Heart, lung & circulation</jtitle><addtitle>Heart Lung Circ</addtitle><date>2019-10</date><risdate>2019</risdate><volume>28</volume><issue>10</issue><spage>1571</spage><epage>1579</epage><pages>1571-1579</pages><issn>1443-9506</issn><eissn>1444-2892</eissn><abstract>Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage.
This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.</abstract><cop>Australia</cop><pub>Elsevier B.V</pub><pmid>31104887</pmid><doi>10.1016/j.hlc.2019.04.014</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1443-9506 |
| ispartof | Heart, lung & circulation, 2019-10, Vol.28 (10), p.1571-1579 |
| issn | 1443-9506 1444-2892 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2232086121 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized - pharmacology Anticholesteremic Agents - pharmacology Atherosclerosis Australia - epidemiology Cardiovascular Diseases - drug therapy Cardiovascular Diseases - epidemiology Cardiovascular risk Humans Incidence Lipids PCSK9 inhibitors Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - immunology Treatment Outcome |
| title | Status of PCSK9 Monoclonal Antibodies in Australia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A56%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Status%20of%20PCSK9%20Monoclonal%20Antibodies%20in%20Australia&rft.jtitle=Heart,%20lung%20&%20circulation&rft.au=Scherer,%20Daniel%20J&rft.date=2019-10&rft.volume=28&rft.issue=10&rft.spage=1571&rft.epage=1579&rft.pages=1571-1579&rft.issn=1443-9506&rft.eissn=1444-2892&rft_id=info:doi/10.1016/j.hlc.2019.04.014&rft_dat=%3Cproquest_cross%3E2232086121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2232086121&rft_id=info:pmid/31104887&rft_els_id=S1443950619303543&rfr_iscdi=true |